Playback speed
10 seconds
ASCO 2022 on the rEECur Trial: High-Dose Ifosfamide as a SoC for Recurrent and Primary Refractory Ewing Sarcoma
By
ecancer
FEATURING
Martin Mccabe
By
ecancer
FEATURING
Martin Mccabe
28 views
June 24, 2022
Comments 0
Login to view comments.
Click here to Login